Related Experiment Video
Updated: May 31, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Weak economic evidence for WHO's essential cancer medicines for Africa
Aron E van der Steege1, James Humuza2, Cyprien Shyirambere3
1IQ Health, Radboud University Medical Center, Nijmegen, The Netherlands aronvdsteege@gmail.com.
Introduction:
The WHO Model Lists of Essential Medicines (MLEM and MLEMc) guide national medicine selection, particularly in low-income and lower middle-income countries (LMICs). Concerns exist about the adequacy and transferability of economic evidence supporting recent cancer medicine additions.
Methods:
We systematically examined modifications to cancer medicines on the WHO MLEM(c) between 2017 and 2023 and assessed their adoption into National Essential Medicines Lists (NEMLs) and NEMLs for children (NEMLcs) of African LMICs (2019-2024). Economic evidence was classified as cost or cost-effectiveness data and transferability to African LMIC contexts was evaluated.
Results:
Of 160 modifications, 11% included cost data and 9% cost-effectiveness evidence. All identified cost-effectiveness studies showed low transferability to African LMIC settings. Among 46 African LMICs, 23 NEMLs and 6 NEMLcs were available. Median adoption of new cancer medicines was 23% for NEMLs and 13% for NEMLcs.
Conclusion:
Recent WHO MLEM(c) modifications to cancer medicines are rarely supported by robust, context-specific economic evidence yet several have been adopted in African LMICs. Stronger requirements for economic evaluations are essential to ensure the affordability, sustainability and policy relevance of WHO essential medicine recommendations.
Related Concept Videos
Cancer Survival Analysis
Drugs that Stabilize Microtubules
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Destabilize Microtubules
